Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Mar 8;21(2):331–342. doi: 10.1089/scd.2010.0587

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2012, Mary Ann Liebert, Inc.

PMC Copyright notice

FIG. 7. — Effects of the β1 integrin blocking antibody on ESC-EC angiogenesis. (A) Quantitative analysis of the proportion of angiogenic aggregates after 72 h of β1 integrin blocking. Nonangiogenic and angiogenic vascular phenotypes were scored among at least 96 ESC-EC aggregates. (B) The development of the angiogenic aggregate after β1 integrin blocking antibody treatment (a–c); (d–f) IgG-treated control. (C) Quantitative analysis of the average vascularized area in day 3 angiogenic aggregates after β1 integrin blocking antibody treatment. (D) Quantitative analysis of the ESC-EC survival time in angiogenic aggregates after β1 integrin blocking antibody treatment. Data are the mean±SD of 3 independent experiments. An asterisk (*) indicates a significant difference (P<0.01). Scale bar, 200 μm.